SMIP004
Modify Date: 2025-08-25 16:40:50
SMIP004 structure
|
Common Name | SMIP004 | ||
|---|---|---|---|---|
| CAS Number | 143360-00-3 | Molecular Weight | 205.29600 | |
| Density | 1.003g/cm3 | Boiling Point | 343ºC at 760mmHg | |
| Molecular Formula | C13H19NO | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 206.1ºC | |
Use of SMIP004SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial: |
| Name | N-(4-butyl-2-methylphenyl)acetamide |
|---|---|
| Synonym | More Synonyms |
| Description | SMIP004 is a novel inducer of cancer-cell selective apoptosis of human prostate cancer cells, it was found to downregulate SKP2 and to stabilize p27.IC50 Value: 1.09 uM (MTT assay in LNCaP-S14 cells) [1]Target: Apoptosis inducer; SKP2in vitro: Whereas SMIP012 and 016 were moderately toxic in normal fibroblasts, SMIPs 001 and 004 showed substantial cancer cell specificity being at least five times more potent in LNCaP-S14 than in IMR90 cells , treatment with either MG132 or SMIP004 increased p27 half-life to > 6 h [1]. Both SMIP001 and 004 led to a strong increase in the recruitment of p27 to CDK2, while SMIP001 also slightly increased coprecipitation of p21 (Figure 6c). SMIP004 also reduced the amounts of cyclins E and A retrieved with CDK2. This was paralleled by a marked downregulation of cyclins E and A upon SMIP004 treatment. SMIP004 decreased the levels of positive cell cycle regulators, upregulated cyclin-dependent kinase inhibitors, and resulted in G1 arrest, inhibition of colony formation in soft agar, and cell death [2].in vivo: SMIP004 potently inhibits the growth of prostate and breast cancer xenografts in mice [2].Clinical trial: |
|---|---|
| Related Catalog | |
| References |
| Density | 1.003g/cm3 |
|---|---|
| Boiling Point | 343ºC at 760mmHg |
| Molecular Formula | C13H19NO |
| Molecular Weight | 205.29600 |
| Flash Point | 206.1ºC |
| Exact Mass | 205.14700 |
| PSA | 29.10000 |
| LogP | 3.36900 |
| Vapour Pressure | 7.24E-05mmHg at 25°C |
| Index of Refraction | 1.539 |
| Storage condition | 2-8℃ |
| HS Code | 2924299090 |
|---|
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
| acetic acid-(4-butyl-2-methyl-anilide) |
| Essigsaeure-(4-butyl-2-methyl-anilid) |
| Acetamide,N-(4-butyl-2-methylphenyl) |
| 6-Acetamino-3-butyl-toluol |
| 2-methyl-4-butylacetanilide |
| N1-(4-butyl-2-methylphenyl)acetamide |
| SMIP004 |